Luxturna/Voretigene — FDA’s First AAV Approval

Shen Lin
Shen Lin
Sep 7, 2018 · 6 min read
A bottle of Luxturna/Voretigene

When FDA first announced its approval of Luxturna (voretigene neparvovec-rzyl), sponsored by Spark Therapeutic, Inc in December 2017 the FDA Commissioner, Scott Gottleib made a press release about how gene therapy has become a breakthrough in the treatment of rare, intractable illnesses. It was also one of three gene therapy approvals in one incredible year for the agency, which has traditionally taken a…

Keep the story going. Sign up for an extra free read.

You've completed your member preview for this month, but when you sign up for a free Medium account, you get one more story.
Already have an account? Sign in

Shen Lin

Written by

Shen Lin

Gene Therapy Research Scientist working at a small biotech company. Blogging all things life and science since 2013.

Welcome to a place where words matter. On Medium, smart voices and original ideas take center stage - with no ads in sight. Watch
Follow all the topics you care about, and we’ll deliver the best stories for you to your homepage and inbox. Explore
Get unlimited access to the best stories on Medium — and support writers while you’re at it. Just $5/month. Upgrade